Should I buy or sell PaxMedica stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PaxMedica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PXMD shares. View PXMD analyst ratings or view top-rated stocks .

What is PaxMedica's stock price target for 2024?

1 Wall Street analysts have issued twelve-month price targets for PaxMedica's shares. Their PXMD share price targets range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 275.0% from the stock's current price. View analysts price targets for PXMD or view top-rated stocks among Wall Street analysts .

How have PXMD shares performed in 2024?

PaxMedica's stock was trading at $0.7570 at the start of the year. Since then, PXMD shares have increased by 5.7% and is now trading at $0.7999. View the best growth stocks for 2024 here .

Are investors shorting PaxMedica?

PaxMedica saw a decline in short interest in March. As of March 31st, there was short interest totaling 133,700 shares, a decline of 75.8% from the March 15th total of 552,300 shares. Based on an average daily volume of 238,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.1% of the shares of the company are sold short. View PaxMedica's Short Interest .

When is PaxMedica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PXMD earnings forecast .

When did PaxMedica's stock split?

Shares of PaxMedica reverse split on the morning of Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did PaxMedica IPO?

PaxMedica (PXMD) raised $9 million in an IPO on Friday, August 26th 2022. The company issued 1,600,000 shares at a price of $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. served as the underwriters for the IPO.

How do I buy shares of PaxMedica?

Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PXMD

PaxMedica (PXMD) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free PXMD Stock Alerts

$0.80

+0.14 (+21.22%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.60
▼
$0.89
50-Day Range: $0.41
▼
$0.84
52-Week Range: $0.37
▼
$38.93

Volume: 3.02 million shs
Average Volume: 2.04 million shs
Market Capitalization: $5.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Get PaxMedica alerts:

PaxMedica MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 275.0% Upside
$3.00 Price Target
Short Interest: Healthy
2.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 8 Articles This Week
Insider Trading: Selling Shares
$212 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
PaxMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
PaxMedica has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.12% of the float of PaxMedica has been sold short.
Short Interest Ratio / Days to Cover
PaxMedica has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in PaxMedica has recently decreased by 75.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PaxMedica does not currently pay a dividend.
Dividend Growth
PaxMedica does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PXMD.

3.2

News and Social Media Coverage

News Sentiment
PaxMedica has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for PaxMedica this week, compared to 1 article on an average week.
Search Interest
8 people have searched for PXMD on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added PaxMedica to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PaxMedica insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $212.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of PaxMedica is held by insiders.
Percentage Held by Institutions
Only 4.90% of the stock of PaxMedica is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of PaxMedica is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PaxMedica is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PaxMedica has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About PaxMedica Stock (NASDAQ:PXMD)

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

PXMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PXMD Stock News Headlines

April 12, 2024 | finanznachrichten.de

PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

April 12, 2024 | markets.businessinsider.com

Nasdaq Down 300 Points; BlackRock Posts Upbeat Earnings

April 17, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

April 12, 2024 | msn.com

Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

April 12, 2024 | investorplace.com

Why Is PaxMedica (PXMD) Stock Up 93% Today?

April 12, 2024 | investorplace.com

Why Is PaxMedica (PXMD) Stock Up 93% Today?

April 11, 2024 | msn.com

PaxMedica shares soar 125% post-market on drug update

April 11, 2024 | finance.yahoo.com

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

April 17, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

April 11, 2024 | globenewswire.com

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

April 9, 2024 | theglobeandmail.com

PaxMedica (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Conditions

March 23, 2024 | theglobeandmail.com

PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

March 13, 2024 | globenewswire.com

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

March 6, 2024 | morningstar.com

PaxMedica Inc Ordinary Shares PXMD

February 23, 2024 | benzinga.com

PaxMedica Stock (NASDAQ:PXMD), Short Interest Report

January 29, 2024 | theglobeandmail.com

PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD

January 18, 2024 | finance.yahoo.com

IBN Highlights PaxMedica's Video Release on Transformative ASD Study

January 17, 2024 | theglobeandmail.com

IBN Highlights PaxMedica’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

January 17, 2024 | finance.yahoo.com

PaxMedica on Promising Path to Address Unmet ASD Needs

December 22, 2023 | finance.yahoo.com

PaxMedica Files 8-K Following Nasdaq Compliance Achievement

December 20, 2023 | finance.yahoo.com

PaxMedica, Inc. (PXMD) Interactive Stock Chart - Yahoo Finance

December 19, 2023 | finance.yahoo.com

PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline

December 12, 2023 | finance.yahoo.com

PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report

December 8, 2023 | finance.yahoo.com

PaxMedica CEO Featured in Just-Released Fireside Chat Video

December 6, 2023 | finance.yahoo.com

PaxMedica Releases Fireside Chat Video with CEO Howard Weisman

December 5, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation

December 4, 2023 | benzinga.com

PaxMedica Stock (NASDAQ:PXMD), Analyst Ratings, Price Targets, Predictions

See More Headlines

Receive PXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/17/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PXMD
CUSIP: N/A
CIK: 1811623
Web: www.paxmedica.com
Phone: 914-987-2876
Fax: N/A
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +347.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($24.4176)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -956.84%
Return on Assets: -388.94%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.16
Quick Ratio: 3.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 1.46

Miscellaneous

Outstanding Shares: 7,410,000
Free Float: 7,193,000
Market Cap: $4.97 million
Optionable: Not Optionable
Beta: 0.61

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Howard J. Weisman (Age 65)
CEO & Chairman
Comp: $640k
Mr. Stephen Douglas Sheldon (Age 44)
CFO & COO
Comp: $198.66k
Dr. David W. Hough M.D. (Age 67)
Chief Medical Officer
Comp: $327.5k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PXMD Stock Analysis - Frequently Asked Questions

Should I buy or sell PaxMedica stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PaxMedica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PXMD shares.
View PXMD analyst ratings or view top-rated stocks.
What is PaxMedica's stock price target for 2024?: 1 Wall Street analysts have issued twelve-month price targets for PaxMedica's shares. Their PXMD share price targets range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 275.0% from the stock's current price.
View analysts price targets for PXMD or view top-rated stocks among Wall Street analysts.
How have PXMD shares performed in 2024?: PaxMedica's stock was trading at $0.7570 at the start of the year. Since then, PXMD shares have increased by 5.7% and is now trading at $0.7999.
View the best growth stocks for 2024 here.
Are investors shorting PaxMedica?: PaxMedica saw a decline in short interest in March. As of March 31st, there was short interest totaling 133,700 shares, a decline of 75.8% from the March 15th total of 552,300 shares. Based on an average daily volume of 238,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.1% of the shares of the company are sold short.
View PaxMedica's Short Interest.

When is PaxMedica's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PXMD earnings forecast.
When did PaxMedica's stock split?: Shares of PaxMedica reverse split on the morning of Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.
When did PaxMedica IPO?: PaxMedica (PXMD) raised $9 million in an IPO on Friday, August 26th 2022. The company issued 1,600,000 shares at a price of $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. served as the underwriters for the IPO.
How do I buy shares of PaxMedica?: Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PXMD) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial